Harbin Pharmaceutical Group Co., Ltd.

Equities

600664

CNE0000009T3

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
3.01 CNY +6.36% Intraday chart for Harbin Pharmaceutical Group Co., Ltd. +7.89% -10.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Harbin Pharma to Upgrade Subsidiary's Production Base for 50 Million Yuan MT
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Roxatidine Hydrochloride for Injection of Harbin Pharma's Subsidiary Passes Drug Regulator's Evaluation MT
Harbin Pharmaceutical Group's Cefotiam Hydrochloride Selected for China's Centralized Procurement Bid MT
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Harbin Pharmaceutical Group Co., Ltd.(XSSC:600664) added to S&P Global BMI Index CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Jian´anxi Food Technology Co., Ltd announced that it expects to receive $20 million in funding from Harbin Pharmaceutical Group Co., Ltd. CI
Ecmoho Limited and Harbin Pharmaceutical Group Announce Joint Launch of New Iron Supplement Product CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
News Highlights : Top Company News of the Day DJ
News Highlights : Top Company News of the Day DJ
News Highlights : Top Company News of the Day DJ
News Highlights : Top Company News of the Day DJ
Chart Harbin Pharmaceutical Group Co., Ltd.
More charts
Harbin Pharmaceutical Group Co is a China-based company mainly engaged in pharmaceutical research and development. The Company's main businesses are innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals, covering the business sectors of antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The Company’s main products include calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, Xingaizhonggai high calcium tablets, etc.
More about the company
  1. Stock Market
  2. Equities
  3. 600664 Stock
  4. News Harbin Pharmaceutical Group Co., Ltd.
  5. Harbin Pharmaceutical Group's Cefotiam Hydrochloride Selected for China's Centralized Procurement Bid